{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:37:49Z","timestamp":1789821469583,"version":"4.0.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jchf.2017.03.003","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T14:02:26Z","timestamp":1494511346000},"page":"399-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure"],"prefix":"10.1016","volume":"5","author":[{"given":"Milton","family":"Packer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Lucien","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"DeMets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2017.03.003_bib1","first-page":"S547","article-title":"The effects of BTS 49465 on blood pressure and peripheral arteriolar and venous tone in normal volunteers","volume":"2","author":"Cowley","year":"1984","journal-title":"J\u00a0Hypertens Suppl"},{"key":"10.1016\/j.jchf.2017.03.003_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0002-8703(87)90021-4","article-title":"Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure","volume":"113","author":"Kessler","year":"1987","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2017.03.003_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00005344-198807000-00002","article-title":"Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure","volume":"12","author":"Kessler","year":"1988","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jchf.2017.03.003_bib4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0735-1097(93)90404-O","article-title":"Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors","volume":"22","author":"Gottlieb","year":"1993","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.03.003_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/bmj.297.6642.169","article-title":"Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects","volume":"297","author":"Cowley","year":"1988","journal-title":"BMJ"},{"key":"10.1016\/j.jchf.2017.03.003_bib6","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/0735-1097(92)90448-V","article-title":"Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure","volume":"20","author":"Cavero","year":"1992","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.03.003_bib7","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/BF02018268","article-title":"Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failure","volume":"4","author":"Riegger","year":"1990","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jchf.2017.03.003_bib8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/eurheartj\/14.6.836","article-title":"Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy","volume":"14","author":"Dakak","year":"1993","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.03.003_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0735-1097(93)90816-J","article-title":"Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study","volume":"22","author":"Packer","year":"1993","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.03.003_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0167-5273(93)90176-H","article-title":"Placebo-controlled trial of flosequinan in moderate heart failure. The possible importance of aetiology and method of analysis in the interpretation of the results of heart failure trials","volume":"38","author":"Cowley","year":"1993","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2017.03.003_bib11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2125.1990.tb03674.x","article-title":"The effects of flosequinan on submaximal exercise in patients with chronic cardiac failure","volume":"29","author":"Elborn","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jchf.2017.03.003_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1161\/01.CIR.88.2.492","article-title":"Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the Flosequinan-ACE inhibitor trial (FACET)","volume":"88","author":"Massie","year":"1993","journal-title":"Circulation"},{"issue":"1 Pt 1","key":"10.1016\/j.jchf.2017.03.003_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0002-8703(96)90401-9","article-title":"Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan","volume":"132","author":"Massie","year":"1996","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2017.03.003_bib14","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/00005344-199006000-00007","article-title":"Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog","volume":"15","author":"Greenberg","year":"1990","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"2 Pt 1","key":"10.1016\/j.jchf.2017.03.003_bib15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0002-8703(91)90723-U","article-title":"Flosequinan: a vasodilator with positive inotropic activity","volume":"121","author":"Corin","year":"1991","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2017.03.003_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1476-5381.1992.tb14367.x","article-title":"Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure","volume":"106","author":"Perreault","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jchf.2017.03.003_bib17","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/0735-1097(92)90179-Q","article-title":"Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure","volume":"20","author":"Burstein","year":"1992","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.03.003_bib18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/00005344-199405000-00015","article-title":"Assessment of flosequinan's direct effect on human arterial, venous, and cardiac muscle: comparison with other classes of agents used to treat heart failure","volume":"23","author":"Weishaar","year":"1994","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jchf.2017.03.003_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0014-2999(96)00946-6","article-title":"Mechanisms of positive inotropic action of flosequinan, hydralazine, and milrinone on mammalian myocardium","volume":"321","author":"Miao","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jchf.2017.03.003_bib20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00005344-199503000-00005","article-title":"Actions of the novel vasodilator, flosequinan, in isolated ventricular cardiomyocytes","volume":"25","author":"Kelso","year":"1995","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jchf.2017.03.003_bib21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00005344-198909000-00009","article-title":"Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite","volume":"14","author":"Falotico","year":"1989","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jchf.2017.03.003_bib22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1476-5381.1993.tb13513.x","article-title":"Effect of flosequinan on ischaemia-induced arrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat","volume":"108","author":"Jones","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jchf.2017.03.003_bib23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1476-5381.1993.tb13625.x","article-title":"Cellular mechanism of the positive inotropic effect of hydralazine in mammalian myocardium","volume":"109","author":"Hurrell","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jchf.2017.03.003_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/cvr\/20.3.215","article-title":"Correlation between effects of hydralazine on force and on the adenyl cyclase system of ventricular myocardium in dogs and cats","volume":"20","author":"Rabinowitz","year":"1986","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jchf.2017.03.003_bib25","first-page":"269","article-title":"The mechanisms of the inotropic and chronotropic actions of hydralazine on rat isolated atria","volume":"255","author":"Songkittiguna","year":"1982","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.jchf.2017.03.003_bib26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-92-5-600","article-title":"Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects","volume":"92","author":"Chatterjee","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2017.03.003_bib27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/hrt.56.2.152","article-title":"Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure","volume":"56","author":"Daly","year":"1986","journal-title":"Br Heart J"},{"key":"10.1016\/j.jchf.2017.03.003_bib28","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1172\/JCI111742","article-title":"Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside","volume":"75","author":"Jaski","year":"1985","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jchf.2017.03.003_bib29","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM198903163201101","article-title":"A\u00a0comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure","volume":"320","author":"DiBianco","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.03.003_bib30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0735-1097(86)80231-5","article-title":"Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure","volume":"7","author":"Grose","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.03.003_bib31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0735-1097(00)00759-2","article-title":"Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group","volume":"36","author":"Lowes","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.03.003_bib32","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/eurheartj\/ehp338","article-title":"Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials","volume":"30","author":"Metra","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.03.003_bib33","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.03.003_bib34","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.03.003_bib35","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group","volume":"325","author":"Packer","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.03.003_bib36","series-title":"FDA approved label for Manoplax (flosequinan)","year":"1993"},{"key":"10.1016\/j.jchf.2017.03.003_bib37","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A\u00a0multiple testing procedure for clinical trials","volume":"35","author":"O'Brien","year":"1979","journal-title":"Biometrics"},{"key":"10.1016\/j.jchf.2017.03.003_bib38","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.jchf.2017.03.003_bib39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0002-8703(00)90035-8","article-title":"Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan","volume":"139","author":"Moe","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2017.03.003_bib40","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJM199812173392503","article-title":"A\u00a0dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators","volume":"339","author":"Cohn","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.03.003_bib41","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(96)10488-8","article-title":"Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators","volume":"349","author":"Hampton","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2017.03.003_bib42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.03.003_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1472-8206.1997.tb00173.x","article-title":"Hemodynamic and neurohormonal effects of flosequinan in patients with heart failure","volume":"11","author":"Isnard","year":"1997","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jchf.2017.03.003_bib44","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jacc.2004.04.059","article-title":"Furosemide and the progression of left ventricular dysfunction in experimental heart failure","volume":"44","author":"McCurley","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.03.003_bib45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-1011744","article-title":"Acute changes in plasma renin activity, plasma aldosterone concentration and plasma electrolyte concentrations following furosemide administration in patients with congestive heart failure\u2013interrelationships and diuretic response","volume":"19","author":"Mulder","year":"1987","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jchf.2017.03.003_bib46","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1210\/jcem-59-5-924","article-title":"Hyponatremia in congestive heart failure: implications for neurohormonal activation and responses to orthostasis","volume":"59","author":"Lilly","year":"1984","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jchf.2017.03.003_bib47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.73.2.257","article-title":"Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure","volume":"73","author":"Lee","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.03.003_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00635699","article-title":"Aldosterone and prolactin responsiveness after prolonged treatment of congestive heart failure with captopril","volume":"28","author":"Jungmann","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.jchf.2017.03.003_bib49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1600-0773.1984.tb03641.x","article-title":"Hypokalemia in cardiac decompensation","volume":"54","author":"Johansson","year":"1984","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"10.1016\/j.jchf.2017.03.003_bib50","doi-asserted-by":"crossref","first-page":"28E","DOI":"10.1016\/0002-9149(90)90249-Z","article-title":"Interrelation of electrolytes and renin-angiotensin system in congestive heart failure","volume":"65","author":"Dargie","year":"1990","journal-title":"Am J Cardiol"},{"issue":"6 Pt 1","key":"10.1016\/j.jchf.2017.03.003_bib51","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0002-8703(94)90745-5","article-title":"Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration","volume":"128","author":"Binkley","year":"1994","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2017.03.003_bib52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/heartjnl-2015-308428","article-title":"Ambulatory heart rate range predicts mode-specific mortality and hospitalisation in chronic heart failure","volume":"102","author":"Cubbon","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2017.03.003_bib53","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.amjmed.2015.04.042","article-title":"Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction","volume":"128","author":"Hamill","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2017.03.003_bib54","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jacc.2007.04.079","article-title":"Resting heart rate in cardiovascular disease","volume":"50","author":"Fox","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.03.003_bib55","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A\u00a0comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.03.003_bib56","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"issue":"Suppl B","key":"10.1016\/j.jchf.2017.03.003_bib57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/17.suppl_B.21","article-title":"Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease","volume":"17","author":"Packer","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.03.003_bib58","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.03.003_bib59","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.289.6.712","article-title":"Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study","volume":"289","author":"Krum","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2017.03.003_bib60","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.03.003_bib61","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0735-1097(83)80316-7","article-title":"A\u00a0placebo-controlled trial of captopril in refractory chronic congestive heart failure","volume":"2","year":"1983","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.03.003_bib62","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/01.CIR.94.11.2793","article-title":"Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise","volume":"94","author":"Packer","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.03.003_bib63","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1161\/hc1002.105180","article-title":"Tolerability of beta-blocker initiation and titration in the Metoprolol CR\/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.03.003_bib64","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0167-5273(01)00447-8","article-title":"The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure","volume":"80","author":"van Veldhuisen","year":"2001","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2017.03.003_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199307013290101","article-title":"Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study","volume":"329","author":"Packer","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.03.003_bib66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1071-9164(99)90003-9","article-title":"Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. VEST Withdrawal Substudy Group","volume":"5","author":"Soran","year":"1999","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2017.03.003_bib67","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.03.003_bib68","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/eurheartj\/ehl505","article-title":"Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony","volume":"28","author":"Fruhwald","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.03.003_bib69","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/CIRCHEARTFAILURE.112.000174","article-title":"Brain natriuretic peptide and cardiac resynchronization therapy in patients with mildly symptomatic heart failure","volume":"6","author":"Brenyo","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2017.03.003_bib70","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.jacc.2016.09.936","article-title":"Natriuretic peptides, 6-min walk test, and quality-of-life questionnaires as clinically meaningful endpoints in HF trials","volume":"68","author":"Ferreira","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177917302056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177917302056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T01:59:40Z","timestamp":1719194380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177917302056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S2213177917302056"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2017.03.003","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2017.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}